angiodynamics inc. - ANGO

ANGO

Close Chg Chg %
13.00 -0.11 -0.83%

Open Market

12.89

-0.11 (0.83%)

Volume: 86.36K

Last Updated:

Dec 31, 2025, 1:25 PM EDT

Company Overview: angiodynamics inc. - ANGO

ANGO Key Data

Open

$13.00

Day Range

12.81 - 13.12

52 Week Range

8.27 - 13.99

Market Cap

$535.60M

Shares Outstanding

41.20M

Public Float

38.85M

Beta

0.49

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$0.78

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

409.14K

 

ANGO Performance

1 Week
 
-1.76%
 
1 Month
 
3.79%
 
3 Months
 
10.57%
 
1 Year
 
40.50%
 
5 Years
 
-16.05%
 

ANGO Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 3
Full Ratings ➔

About angiodynamics inc. - ANGO

AngioDynamics, Inc. is a medical device company, which engages in the development, manufacturing, and sale of medical devices for vascular access, surgery, peripheral vascular disease, and oncology. The firm offers ablation systems, fluid management systems, vascular access, angiographic, drainage, thrombolytic, and venous products. It operates through the Med Tech and Med Device segments. The Med Tech segment consists of technology portfolio including Auryon, the thrombus management platform and NanoKnife. The Med Device segment focuses on core, venous, ports, and other oncology products. The company was founded by Howard S. Stern and Eamonn P. Hobbs on February 9, 1988 and is headquartered in Latham, NY.

ANGO At a Glance

AngioDynamics, Inc.
14 Plaza Drive
Latham, New York 12110
Phone 1-518-795-1400 Revenue 292.50M
Industry Medical Specialties Net Income -33,993,000.00
Sector Health Technology Employees 675
Fiscal Year-end 05 / 2026
View SEC Filings

ANGO Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 1.425
Price to Book Ratio 2.285
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -1,494.874
Enterprise Value to Sales 1.247
Total Debt to Enterprise Value 0.011

ANGO Efficiency

Revenue/Employee 433,330.37
Income Per Employee -50,360.00
Receivables Turnover 6.82
Total Asset Turnover 0.979

ANGO Liquidity

Current Ratio 2.209
Quick Ratio 1.395
Cash Ratio 0.734

ANGO Profitability

Gross Margin 50.389
Operating Margin -8.226
Pretax Margin -11.635
Net Margin -11.622
Return on Assets -11.372
Return on Equity -17.497
Return on Total Capital -18.186
Return on Invested Capital -17.229

ANGO Capital Structure

Total Debt to Total Equity 2.157
Total Debt to Total Capital 2.111
Total Debt to Total Assets 1.409
Long-Term Debt to Equity 1.151
Long-Term Debt to Total Capital 1.127
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Angiodynamics Inc. - ANGO

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
316.22M 338.75M 303.91M 292.50M
Sales Growth
+8.66% +7.13% -10.28% -3.76%
Cost of Goods Sold (COGS) incl D&A
169.94M 183.30M 162.26M 145.11M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
29.50M 33.17M 27.75M 23.82M
Depreciation
10.04M 14.38M 14.70M 13.50M
Amortization of Intangibles
19.46M 18.79M 13.05M 10.32M
COGS Growth
+11.54% +7.86% -11.47% -10.57%
Gross Income
146.27M 155.46M 141.65M 147.39M
Gross Income Growth
+5.50% +6.28% -8.88% +4.05%
Gross Profit Margin
+46.26% +45.89% +46.61% +50.39%
2022 2023 2024 2025 5-year trend
SG&A Expense
164.15M 173.68M 174.42M 170.56M
Research & Development
30.74M 29.88M 31.51M 26.22M
Other SG&A
133.41M 143.79M 142.91M 144.34M
SGA Growth
+8.15% +5.81% +0.43% -2.21%
Other Operating Expense
343.00K 457.00K 1.07M 886.00K
Unusual Expense
10.25M 32.50M 213.09M 15.89M
EBIT after Unusual Expense
(28.47M) (51.18M) (246.93M) (39.95M)
Non Operating Income/Expense
(790.00K) (554.00K) 55.30M 5.92M
Non-Operating Interest Income
- - 1.61M 978.00K
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- - 688.00K 2.70M
-
Interest Expense Growth
- - -20.09% +292.73%
-
Gross Interest Expense
- - 688.00K 2.70M
-
Interest Capitalized
- - - -
-
Pretax Income
(29.95M) (54.44M) (191.64M) (34.03M)
Pretax Income Growth
+16.93% -81.77% -252.04% +82.24%
Pretax Margin
-9.47% -16.07% -63.06% -11.63%
Income Tax
(3.40M) (2.00M) (7.29M) (39.00K)
Income Tax - Current - Domestic
120.00K 129.00K 318.00K 621.00K
Income Tax - Current - Foreign
186.00K 187.00K 361.00K 328.00K
Income Tax - Deferred - Domestic
- (3.42M) (207.00K) (7.04M)
Income Tax - Deferred - Foreign
(293.00K) (2.10M) (929.00K) (988.00K)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(26.55M) (52.44M) (184.35M) (33.99M)
Minority Interest Expense
- - - -
-
Net Income
(26.55M) (52.44M) (184.35M) (33.99M)
Net Income Growth
+15.85% -97.54% -251.53% +81.56%
Net Margin Growth
-8.40% -15.48% -60.66% -11.62%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(26.55M) (52.44M) (184.35M) (33.99M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(26.55M) (52.44M) (184.35M) (33.99M)
EPS (Basic)
-0.6805 -1.3283 -4.588 -0.8321
EPS (Basic) Growth
+17.29% -95.19% -245.40% +81.86%
Basic Shares Outstanding
39.01M 39.48M 40.18M 40.85M
EPS (Diluted)
-0.6805 -1.3283 -4.588 -0.8321
EPS (Diluted) Growth
+17.29% -95.19% -245.40% +81.86%
Diluted Shares Outstanding
39.01M 39.48M 40.18M 40.85M
EBITDA
11.28M 14.49M (6.10M) (244.00K)
EBITDA Growth
-0.44% +28.50% -142.06% +96.00%
EBITDA Margin
+3.57% +4.28% -2.01% -0.08%

Snapshot

Average Recommendation BUY Average Target Price 19.333
Number of Ratings 3 Current Quarters Estimate -0.09
FY Report Date 02 / 2026 Current Year's Estimate -0.33
Last Quarter’s Earnings -0.10 Median PE on CY Estimate N/A
Year Ago Earnings -0.15 Next Fiscal Year Estimate -0.157
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 3 3 3 3
Mean Estimate -0.09 -0.04 -0.33 -0.16
High Estimates -0.08 -0.03 -0.32 -0.13
Low Estimate -0.10 -0.04 -0.34 -0.18
Coefficient of Variance -11.11 -15.75 -3.03 -16.06

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 3 3 3
OVERWEIGHT 0 0 0
HOLD 0 0 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Angiodynamics Inc. in the News